- In March 2024, Medtronic partnered with Google to integrate artificial intelligence (AI) into gastric electrical stimulators. This strategic collaboration aims to create devices that dynamically adjust to patient-specific needs, enhancing treatment personalization and effectiveness. Leveraging AI, this initiative seeks to redefine innovation in medical devices, setting a benchmark for patient care advancements and improving outcomes significantly
- In December 2023, The FDA granted conditional approval to Enterra Medical’s implantable electrical stimulation device, addressing gastroparesis symptoms such as nausea and vomiting. The Enterra II system, comprising the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, offers promising symptom relief. This approval highlights advancements in managing gastroparesis, showcasing the device's potential to improve patient quality of life
